



THE CANADIAN CANCER RESEARCH CONFERENCE | LA CONFÉRENCE CANADIENNE SUR LA RECHERCHE SUR LE CANCER



# IN-PERSON PROGRAM

## PROGRAMME DE LA

### CONFÉRENCE EN PERSONNE

---

November 12 - 14, 2023

Halifax, NS

12 au 14 novembre 2023

Halifax, NS

[ccra-acrc.ca/conference](https://ccra-acrc.ca/conference)

# CONFERENCE OVERVIEW – In Person

## Sunday, November 12, 2023

8:00 am	Breakfast				
9:00 am	Welcome Remarks				
10:30 am	Plenary Session – Liquid Biopsies				
12:00 pm	<b>Lunch and Poster Exhibit Session</b> 12:20 – Pan-Canadian Cancer Data Strategy: Efforts to advance cancer data priorities <i>Canadian Partnership Against Cancer Sponsored Presentation</i> 1:00 – The Terry Fox Research Institute, Program Portfolio and Plans <i>Terry Fox Research Institute Sponsored Session</i>				
1:30 pm	Lightning Sessions				
	Bioinformatics, Big Data, AI and Technology	Survivorship	Immunotherapy	Cancer Clinical Research and Trials	Health Services Research, Health Economics, and Implementation Science
2:00 pm	Transition				
2:10 pm	Concurrent Sessions				
	Health Equity	Innovations in Clinical Trials	Pediatric oncology Targets, Testing, Trials and Transitions	Advances in Cancer Immunotherapy	WORKSHOP – DEI in Research Funding and Diversity in Science
3:40 pm	Break				
4:10 pm	Plenary Session – AI Across the Research Spectrum				

## Monday, November 13, 2023

8:00 am	<b>Breakfast</b> Mi'kma'ki Showcase: Trevor Gould & Ben Marmen				
9:00 am	Concurrent Sessions				
	Improving the Cancer Journey of First Nations, Inuit and Métis	Enhancing Palliative, End-of-Life, and Survivorship Experience	Molecular Drivers of Cancer Metastases	Cancer Research from Atlantic Canada	WORKSHOP – AI Tools and Methods
10:30 am	Transition				
10:40 am	Lightning Sessions				
	Metastasis	Screening, Early Detection, Diagnosis and Prognosis	Precision Medicine and Biomarkers	Health Disparities and Equity	Pediatric Cancer
11:10 am	Break				
11:40 am	Concurrent Sessions				
	Adolescent and Young Adult Cancer	Tumour Microenvironment	Respecting Partnerships, Governance and Information for change in First Nations, Inuit and Métis cancer care	Crises Affecting Healthcare	Canadian Partnership for Tomorrow's Health: Canada's largest population laboratory for cancer research
1:10 pm	<b>Lunch and Poster Exhibit Session</b> 1:30 – CCRA Open Meeting				
2:40 pm	Plenary Session – Clinical Innovations in the Real World				
4:10 pm	Break				
4:40 pm	Concurrent Sessions				
	The Gut Microbiome for Precision Oncology	Advances in Cancer Biology	Honoring Culture, Traditions and Language of First Nations, Inuit and Métis	Overcoming Treatment Resistance in Cancers	WORKSHOP – Patient Engagement

## Tuesday, November 14, 2023

6:15 am	Terry Fox Run				
8:00 am	Breakfast				
9:00 am	Concurrent Sessions				
	Reducing Your Risk of Cancer	Recent Advances in Cancer Treatment	Supporting First Nations, Inuit and Métis Cancer Strategies through Research	Networked Cancer Research in Canada	Multi-omics and Epigenetics
10:30 am	Transition				
10:40 am	Lightning Sessions				
	Metabolism	Patient Experience and Advocacy	Drug Discovery, Design, Delivery and Resistance	Genetics and Epigenetics	Cancer Risk and Primary Prevention
11:10 am	Break				
11:40 am	Plenary Session – Environment and Cancer				
1:10 pm	Closing Remarks				

\*Scientific Program subject to change

# APERÇU DU PROGRAMME – En Personne

## Dimanche 12 novembre 2023

8 h	Déjeuner				
9 h	Mot de bienvenue				
10 h 30	Séance plénière – Les biopsies liquides				
12 h	<b>Dîner et séance de présentations par affiches et d'exposition</b> 12h20 - La stratégie pancanadienne de données sur le cancer : efforts visant à faire avancer les priorités en matière de données sur le cancer – Présentation parrainée par le Partenariat canadien contre le cancer 13 h - L'Institut de recherche Terry Fox : portefeuille de programmes et projets – Séance parrainée par l'Institut de recherche Terry Fox				
	<b>Séances éclair</b>				
13 h 30	La bio-informatique, les mégadonnées, l'IA et la technologie	La survie	L'immunothérapie	La recherche et les essais cliniques sur le cancer	La recherche sur les services de santé, l'économie de la santé et la science de la mise en œuvre
14 hr	Transition				
	<b>Séances simultanées</b>				
14 h 10	L'équité en santé	Les innovations dans les essais cliniques	L'oncologie pédiatrique : cibles, tests, essais et transitions	Progrès accomplis dans l'immunothérapie contre le cancer	ATELIER – L'EDI dans le financement de la recherche et la diversité en sciences
15 h 40	Pause				
16 h 10	Séance plénière – L'IA dans tous les domaines de la recherche				

## Lundi 13 novembre 2023

8 hr	<b>Déjeuner</b> Mi'kma'ki Showcase: Trevor Gould & Ben Marmen				
	<b>Séances simultanées</b>				
9 hr	Améliorer le parcours face au cancer des Premières Nations, des Inuits et des Métis	Améliorer les expériences des soins palliatifs, des soins de fin de vie et de la survie	Les mécanismes moléculaires à l'origine des métastases du cancer	Recherches sur le cancer provenant du Canada atlantique	ATELIER – Méthodes et outils liés à l'IA
10 h 30	Transition				
	<b>Séances éclair</b>				
10 h 40	Les métastases	Le dépistage, la détection précoce, le diagnostic et le pronostic	La médecine de précision et les biomarqueurs	Les disparités et l'équité en matière de santé	Les cancers pédiatriques
11 h 10	Pause				
	<b>Séances simultanées</b>				
11 h 40	Le cancer chez les adolescents et les jeunes adultes	Le micro-environnement tumoral	Respecter les partenariats, la gouvernance et l'information en faveur du changement dans les soins contre le cancer offerts aux Premières Nations, aux Inuits et aux Métis	Les crises touchant les soins de santé	Le Partenariat canadien pour la santé de demain : le plus grand laboratoire démographique du Canada pour la recherche sur le cancer
13 h 10	<b>Dîner et séance de présentations par affiches et d'exposition</b> 13 h 30 - Réunion ouverte de l'ACRC				
14 h 40	Séance plénière – Les innovations cliniques dans le monde réel				
16 h 10	Pause				
	<b>Séances simultanées</b>				
16 h 40	Le microbiome intestinal pour l'oncologie de précision	Progrès accomplis dans la biologie du cancer	Respecter la culture, les traditions et les langues des Premières Nations, des Inuits et des Métis	Surmonter la résistance au traitement des cancers	ATELIER – La participation des patients

## Mardi 14 novembre 2023

6 h 15	La course Terry Fox				
8 h	Déjeuner				
	<b>Séances simultanées</b>				
9 h	Réduire votre risque de cancer	Les avancées récentes dans le traitement du cancer	Appuyer les stratégies de lutte contre le cancer chez les Premières Nations, les Inuits et les Métis grâce à la recherche	La recherche sur le cancer en réseau au Canada	La multiomique et l'épigénétique
10 h 30	Transition				
	<b>Séances éclair</b>				
10 h 40	Le métabolisme	L'expérience des patients et la défense de leurs intérêts	La découverte, la conception et l'administration des médicaments, et la résistance à ceux-ci	La génétique et l'épigénétique	Le risque de cancer et la prévention primaire
11 h 10	Pause				
11 h 40	Séance plénière – L'environnement et le cancer				
13 h 10	Mot de la fin				

\* Programme sujet à changement

8:00 am

Breakfast

9:00 am

Welcome Remarks

**Catherine Martin**

*Director Indigenous Engagement, Member of Millbrook Mi'kmaw community*

**Dr. Sara Urowitz**

*Canadian Cancer Research Alliance, Canadian Partnership Against Cancer*

**Dr. Paula Robson**

*Alberta Health Services, Canadian Cancer Research Alliance*

**Dr. Helmut Hollenhorst**

*Nova Scotia Health Cancer Care Program, Dalhousie University*

**Dr. Jim Woodgett**

*Terry Fox Research Institute, Lunenfeld-Tanenbaum Research Institute*

**Dr. Sherri Christian**

*Memorial University of Newfoundland, Beatrice Hunter Cancer Research Institute, Marathon of Hope Cancer Centres, Terry Fox Research Institute*

**Dr. Robin Urquhart**

*Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority*

10:30 am

Plenary Session – Liquid Biopsies

Chairs:

**Dr. Sherri Christian**

*Memorial University of Newfoundland, Beatrice Hunter Cancer Research Institute, Marathon of Hope Cancer Centres, Terry Fox Research Institute*

**Ms. Melissa Coombs**

*Patient Partner*

Predicting Response to Immune Checkpoint Therapy with Extracellular Vesicle Liquid Biopsy

The Clinical Utility of Liquid Biopsies in Lung Cancer

CHARMING Hereditary Cancer: Surveillance for Early Cancer using Cell-Free DNA Sequencing

**Dr. Rodney Ouellette**

*Atlantic Cancer Research Institute*

**Dr. Sameena Khan**

*Princess Margaret Cancer Centre, University of Toronto*

**Dr. Trevor Pugh**

*Princess Margaret Cancer Centre, University of Toronto*

12:00 pm

Lunch and Poster and Exhibit Session

**12:20 – Pan-Canadian Cancer Data Strategy: Efforts to advance cancer data priorities** *Canadian Partnership Against Cancer Sponsored Presentation*

**1:00 – The Terry Fox Research Institute, Program Portfolio and Plans** *Terry Fox Research Institute Sponsored Session*

**Bioinformatics, Big Data, AI and Technology**

Single-cell RNAseq identifies tumour stem-cell fate driven by lipid metabolism in liver cancer

**Dr. Tallulah Andrews**  
University of Western Ontario

Exploring Cell Composition and Molecular Markers in Wilms Tumor for Improved Risk Stratification and Treatment

**Mr. Fabian Bong**  
Dalhousie University

Developing the pan-Canadian Cancer Data Strategy (cancer data strategy) to guide cancer data improvements and implementation efforts

**Ms. Natalie Fitzgerald**  
Canadian Partnership Against Cancer

Gaining insights into high risk AML through the integration of drug screening, RNA-seq, and Epigenetic Profiling

**Miss Safia Safa-tahar-henni**  
IRIC/Université de Montréal

Automated tumour group classification from cancer electronic pathology reports using pre-trained language models

**Dr. Jonathan Simkin**  
BC Cancer, Provincial Health Services Authority

ARS2 Association with subnuclear Paraspeckles: Implications for Hepatocellular Carcinoma Progression and Drug Resistance

**Dr. Gobi Thillainadesan**  
Sunnybrook Research Institute

Privacy Risks of Machine Learning Models: Systematic Review and Meta-Analysis of Membership Inference Attacks and Implications for Data Security

**Dr. Emily Walker**  
Cancer Care Alberta, Alberta Health Services

LncRNAs exhibit subtype-specific expression, survival associations, and cancer-promoting effects in breast cancer

**Miss Marie-Claire Wasson**  
Dalhousie University

**Survivorship**

Virtually Supervised Exercise for People with Advanced Lung Cancer: Feasibility and Physical Function Results

**Dr. Kristin Campbell**  
University of British Columbia

Missed Opportunities in Supporting Informal Cancer Caregiver (and Patient) Health

**Mr. Thomas Christensen**  
Dalhousie University

Adherence to Breast Cancer Screening Guidelines and Risk of Breast Cancer-Specific Death

**Dr. Rebecca Christensen**  
Dalla Lana School of Public Health

Development of a polygenic score to predict cisplatin-induced ototoxicity

**Dr. Britt Drogemoller**  
University of Manitoba

Adjuvant Treatment in High-Grade Serous Endometrial Carcinoma: A Comprehensive Institutional Review

**Dr. Sedighe Esmaeilzade**  
McGill University Health Center

Evaluating the association between pre-diagnostic routine lipid measurements and mortality among breast cancer survivors: A population-based retrospective cohort study

**Miss Shana Kim**  
University of Toronto

Finding Intimacy Without Sex: Exploring the impact of lost intimacy and sexual function after cancer

**Ms. Cecile Proctor**  
University of New Brunswick

Strategies to increase acceptance of referral to smoking cessation at an Ontario regional cancer centre

**Dr. Deborah Saunders**  
Northeast Cancer Centre, Health Sciences North

Mental Health Status of Prostate Cancer Survivors in the Atlantic PATH Cohort

**Dr. Ellen Sweeney**  
Dalhousie University

## Immunotherapy

Combination immunotherapy with Smac mimetics potentiate cytokine-induced death of tumor cells

**Dr. Shawn Beug**  
CHEO Research Institute

The role of the TME on combination temozolomide/nivolumab to treat glioblastoma revealed through computational modelling

**Dr. Morgan Craig**  
Sainte-Justine University Hospital Research  
Centre, Université de Montréal

Exploring immune evasion in breast cancer using novel models of acquired resistance to PD-1/PD-L1 blockade

**Dr. Kabir Khan**  
Sunnybrook Research Institute, University of  
Toronto

Augmenting Cancer Immunotherapy by Inhibition of the Fes Tyrosine Kinase

**Mr. Brian Laight**  
Queen's University

Investigating VSV-based Oncolytic Virus to Overcome ICI-resistant Melanomas

**Miss. Tiffany Lin**  
Goodman Cancer Institute, McGill University

Preclinical Mathematical Models for a Combined Treatment of Chemotherapy and Immunotherapy of Glioblastomas and Optimization of Advanced Treatments

**Ms. Blanche Mongeon**  
Université de Montréal

The long, not short, of it: dual approaches for long-dsRNA based breast cancer therapies

**Dr. Sarah Poynter**  
Wilfrid Laurier University

T cell-specific deletion of PRMT7 favors an immune active anti-tumoral microenvironment for melanoma

**Dr. Nivine Srouf**  
Lady Davis Institute, McGill University

---

## Cancer Clinical Research and Trials

Comparative Effectiveness of Salvage Chemotherapy Regimens and Chimeric Antigen T-cell Receptor Therapies in Relapsed and Refractory Diffuse Large B Cell Lymphoma: A Network Meta-Analysis of Clinical Trials

**Dr. Mahmood AminiLari**  
University Health Network

Anti-cancer immune response induced by cytokines

**Dr. Alexandra Berger**  
Princess Margaret Cancer Centre

The untapped therapeutic potential of cholesterol-lowering drugs in solid tumors: the case of a cholesterol embargo on top of standard therapy in advanced pancreatic cancer NCT04862260

**Dr. Anne Gangloff**  
Laval University

Ascites interleukin-10 levels and oncological outcomes in ovarian cancer

**Dr. Gabriel Levin**  
Jewish General Hospital

Proteomics paves the way for personalized treatment of ductal carcinoma in situ: Analysis of tumor cores reveals proteomic and metabolic vulnerabilities and informs therapeutic strategies

**Dr. Gerald Batist**  
Lady Davis Institute

Efficacy, effectiveness and immunogenicity of a reduced HPV vaccination schedule: a systematic review

**Mr. Joshua Montroy**  
Public Health Agency of Canada

BOLD-100-001: A Phase 1b/2a Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Pre-Treated Advanced Gastrointestinal Cancers: Interim Safety Results

**Mr. Malcolm Snow**  
Bold Therapeutics, Inc.

Shooting for the Moon: Can we cut cancer mortality by 50% by 2050?

**Dr. Darren Brenner**  
*University of Calgary*

Lymphoma Diagnosis Pathway Implementation in Alberta

**Mr. Tim Buckland**  
*Alberta Health Services*

The Cost of Cancer: A Societal View

**Ms. Roxanne Garaszczuk**  
*Canadian Partnership Against Cancer*

Cancer in Canada 2023

**Dr. Jennifer Gillis**  
*Canadian Cancer Society*

Pathways to cancer care after a suspected cancer diagnosis in the emergency department: A survey of emergency physicians across Ontario

**Dr. Keerat Grewal**  
*Sinai Health*

Developing Authentic Relationships to Support Cancer Care System & Practice Change: A First Nations Methodology

**Dr. Angeline Letendre**  
*Canadian Indigenous Nurses Association*

Cancer patients' attitudes toward delayed progression on imaging in the absence of improved survival

**Dr. Andrew Robinson**  
*Queen's University*

Estimating Cancer Diagnostic Interval Using Deep Learning Method based on Population-based Real-world Health Data

**Dr. Yuan Xu**  
*University of Calgary*

**2:00 pm**

**Transition**

**2:10 pm**

**CONCURRENT SESSIONS**

---

**Health Equity**

Chair:

**Dr. David Busolo**  
*University of New Brunswick, Faculty of Nursing, Moncton Campus, Beatrice Hunter Cancer Research Institute*

**Sundas Shamshad**  
*Patient Partner*

Prevention of Cervical Cancer in India through Self-Sampling (PCCIS)

**Dr. Mandana Vahabi**  
*Toronto Metropolitan University*

Exploring primary care provider barriers and enablers to implementation of cancer screening with patients experiencing marginalization

**Dr. Arlinda Ruco**  
*St. Francis Xavier University*

Disparities In Clinical Trial Enrolment At A Canadian Comprehensive Cancer Centre: A Fifteen-Year Retrospective Study

**Dr. Gilla Shapiro**  
*Princess Margaret Cancer Centre*

Cancer incidence in people with intellectual or developmental disabilities: Two population-based retrospective cohort studies in Manitoba and Ontario, Canada

**Dr. Alyson Mahar**  
*Queen's University*

---

## Innovations in Clinical Trials

Chair:

**Dr. Wendy Parulekar**

*Canadian Cancer Trials Group, Queen's University*

**David McMullen**

*Patient Partner*

An Overview of Accelerated Clinical Trials (ACT) Canada

Implementation of the Canadian Remote Access Framework for Clinical Trials (CRAFT), a model for decentralized clinical trials (DCT)

Cost-Effectiveness Analysis of the Prostate Cancer Patient Empowerment Program (PC-PEP)

A phase IIb randomized placebo-controlled trial testing a long-chain omega-3 fatty acid MAG-EPA dietary supplement on prostate cancer aggressiveness

**Dr. PJ Devereaux**

*McMaster University*

**Mr. Stephen Sundquist**

*3CTN - Canadian Cancer Clinical Trials Network*

**Ms. Alexandra Nuyens**

*Dalhousie University*

**Dr. Farah Ben Souilah**

*CHU de Québec - Université Laval*

---

## Pediatric Oncology Targets, Testing, Trials and Transitions

Chair:

**Dr. Rebecca Deyell**

*Children's and Women's Health Centre of British Columbia*

**Adrienne Co-Dyre**

*Patient Partner*

Large scale drug screens of human engineered acute leukemias and genetically matched patients

Defining and measuring the value of genetic testing from patients' perspectives: Developing the Patient-reported Genetic testing Utility InDEx (P-GUIDE) for oncology

Canadian innovation in pediatric hematology/oncology clinical trials: An update from the Canadian Pediatric Cancer Consortium (CPCC)

Transition to long-term follow-up care of AYA cancer survivors: multistakeholder perspectives

**Dr. Brian Wilhelm**

*Université de Montréal*

**Dr. Robin Hajeems**

*The Hospital for Sick Children*

**Dr. Rebecca Deyell**

*Children's and Women's Health Centre of British Columbia*

**Dr. Katrin Julia Kaal**

*Nova Scotia Health, Dalhousie University*

---

## Advances in Cancer Immunotherapy

Chair:

**Carol Pierre**

*Patient Partner*

**Dr. Tak Wah Mak**

*University of Toronto, Princess Margaret Cancer Centre*

Metabolic and Neural Regulation of Immunity and Cancer

Investigating STING activation as a translational immunotherapy for soft tissue sarcomas

Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies

**Dr. Tak Wah Mak**

*University of Toronto, Princess Margaret Cancer Centre*

**Ms. Karys Hildebrand**

*University of Calgary*

**Dr. Taha Azad**

*Université de Sherbrooke*

**Dr. Stephen Robbins**

*Lady Davis Institute for Medical Research, Jewish General Hospital*

**Dr. Juliet Daniel**

*McMaster University*

**Dr. Barbara Vanderhyden**

*Ottawa Hospital Research Institute*

**Dr. Kevin Hewitt**

*Dalhousie University*

**Dr. Christine Chambers**

*Dalhousie University*

**3:40 pm**

**Break**

**4:10 pm**

**Plenary Session – AI Across the Research Spectrum**

Chairs:

**Dr. Ali Bashashati**

*University of British Columbia, Vancouver Coastal Health Research Institute*

**Dr. Rosilene Kraft**

*Patient Partner*

Ethics of AI in Radiology

Applications of AI in Healthcare: Case Examples

Development and commercialization of machine learning models to predict disease

**Dr. Manisha Bahl**

*Mass General Research Institute, Harvard University*

**Dr. Muhammad Mamdani**

*Unity Health, St. Michael's Hospital, University of Toronto*

**Dr. John Lewis**

*Faculty of Medicine & Dentistry, University of Alberta*

8:00 am

Breakfast

9:00 am

CONCURRENT SESSIONS

---

## Improving the Cancer Journey of First Nations, Inuit and Métis

Chair:

**Gail Turner**

*Canadian Partnership Against Cancer*

A Qualitative Exploratory Study to Support the Elimination of Cervical Cancer in Canada's Indigenous Communities: Alberta Métis Settlement Perspectives

**Dr. Angeline Letendre**

*Canadian Indigenous Nurses Association*

The Giant Colon - Increasing Colorectal Cancer Screening Rates through Community Engagement: Manitoba

**Mrs. Laryssa Sawchuck**

*CancerCare Manitoba*

Courage, Compassion and Connection: exploring of the pre-diagnosis cancer journey for Labrador's Indigenous populations

**Dr. Jennifer Shea**

*Memorial University*

---

## Enhancing Palliative, End-of-Life, and Survivorship Experiences

Chair:

**Dr. Harvey Chochinov**

*University of Manitoba*

**Sandra Dudych**

*Patient Partner*

The impact of a cancer diagnosis on the short- and long-term income of cancer survivors in Canada

**Dr. Stuart Peacock**

*Canadian Centre for Applied Research in Cancer Control (ARCC)*

Knowledge products to support the knowledge translation of exercise recommendations for people with bone metastases: an experience-based co-design approach

**Dr. Kelcey Bland**

*University of British Columbia*

Edmonton Classification System for Cancer Pain: Comparison of Pain Classification Features and Pain Intensity across Diverse Palliative Care Settings in Canada

**Dr. Mathieos Beylانه**

*University of British Columbia*

The Patient Dignity Question: Eliciting Personhood in Clinical Care

**Dr. Harvey Chochinov**

*University of Manitoba*

---

## Molecular Drivers of Cancer Metastases

Chair:

**Dr. Michael J. Monument**

*Department of Surgery, University of Calgary*

**Dr. Cara MacInnis**

*Patient Partner*

From molecular mechanism to drug candidate, how we stop the vicious cycle of prolactin-accelerated breast cancer bone metastasis

**Dr. Carrie Shemanko**

*University of Calgary*

Identification and Functional Characterization of Novel Metastasis Driving Mutations from Gastroesophageal Adenocarcinoma

**Mr. Ansley Gnanapragasam**

*McGill University*

Genome-wide CRISPR screens identify a PIK3C3-mTORC1 signaling axis to target in metastatic breast cancer

**Dr. Islam Elkhohi**

*Lady Davis Institute for Medical Research, McGill University*

Role of the lung microenvironment in mediating breast cancer metastasis: molecular cross-talk between The "seed" and the "soil"

**Dr. Alison Allan**

*London Health Science Centre, Western University*

Chair:

**Dr. Jeannette Boudreau**

*Dalhousie University, Beatrice Hunter Cancer Research Institute*

**Barry Darby**

*Patient Partner*

Memory Natural Killer Cell responses and their application in a cell-targeted cancer Immunotherapy

**Mr. Daniel Medina-Luna**

*Dalhousie University*

Revealing the hidden costs: Exploring the financial toxicity of hereditary cancer syndromes

**Dr. Sepideh Rajeziessfahani**

*Memorial University*

Investigating the Translational Potential of circPAX5 in B Cancer cells

**Dr. Parinaz Nasri**

*Université de Moncton*

Improving access to cancer screening is a collaborative endeavour: Perspectives of adult immigrants and refugees in New Brunswick

**Dr. David Busolo**

*University of New Brunswick*

---

#### WORKSHOP – AI Tools and Methods

**Dr. Shirin Abbasinejad Enger**

*McGill University*

**Dr. Parsa Bagherzadeh**

*McGill University*

**Ms. Yujing Zou**

*McGill University*

**10:30 am**

Transition

**10:40 am**

LIGHTNING SESSIONS

---

#### Metastasis

Investigation of roles of DNA methylation inhibition and STING agonist in the treatment of metastatic triple-negative breast cancer

**Dr. Sofiane Berrazouane**

*Lady Davis Institute, McGill University*

Overcoming Therapeutic Resistance by Targeting Ferroptosis in Cancer Cells Undergoing Anastasis

**Miss Rachel Hausman**

*University of British Columbia, BC Cancer Research Centre*

The Benefits and Limitations of dPCR in Detection of Minimal Residual Disease in Stage IV Colorectal Cancer

**Dr. Lucyna Krzywon**

*McGill University Health Centre Research Institute*

Trastuzumab and denosumab in the treatment of metastatic HER2-positive breast cancer: a case series and potential synergistic effect to explain their unusually long survival times

**Mr. Rahman Ladak**

*Schulich School of Medicine and Dentistry, Western University*

High Intratumoral Levels of Coco Leads to Vascular Dysfunction and Increased Tumor Aggressiveness

**Mr. Kevin Lanthier**

*Maisonneuve-Rosemont Research Center*

Exploring a link among protein synthesis, mitochondrial dysfunction, and epithelial-to-mesenchymal transition

**Dr. Stephen Lewis**

*Atlantic Cancer Research Institute*

Promotion of thrombin activatable fibrinolysis inhibitor (TAFI) activation in tumour microenvironment attenuates breast cancer metastasis in vivo

**Ms. Tasnim Reza**

*University of Western Ontario*

Counterbalance between Wnt/ $\beta$ -catenin and ATF2-dependent signalling pathways drives cancer cell invasion and intravasation

**Dr. Konstantin Stoletov**

*University of Alberta*

The impact of verteporfin on lung metastasis in a mouse model of advanced osteosarcoma

**Dr. Alicia Vilorio-Petit**

*University of Guelph*

---

## Screening, Early Detection, Diagnosis and Prognosis

Cancer Stem Cell Marker ALDH1A3 Mediates Invasion in Triple-Negative Breast Cancer by Inducing Plasminogen Activation

**Dr. Alamelu Bharadwaj**  
Dalhousie University

Hospital-based personalized circulating tumor DNA tests for the identification of extremely good prognosis patients with residual Triple Negative Breast Cancer

**Ms. Anna Klemantovich**  
Segal Cancer Centre, Lady Davis Institute,  
Jewish General Hospital

DNA Organization Measurements from All the Individual Cells Within Tissue can be Highly Predictive of Cancer Cell Aggressiveness

**Dr. Calum MacAulay**  
BC Cancer

Self-Collection for Cervix Screening in Never and Under-screened in the British Columbia, Organized Cervix Screening Population-Based Program: Preliminary Program Findings

**Dr. Gina Ogilvie**  
UBC, Women's Health Research Institute

Is Canada prepared for Primary HPV-testing in Cervical Cancer Screening? A national study of the Knowledge, Attitudes, and Beliefs of Under and Adequately Screened Canadians

**Dr. Samara Perez**  
McGill University Health Center

CervixCheck: Outcomes of a digital approach to self-collected cervical screening in a low-uptake region of British Columbia, Canada

**Ms. Laurie Smith**  
BC Cancer and Women's Health Research  
Institute

Characterizing liquid biopsy signature in a chemotherapy resistant model of esophageal adenocarcinoma

**Dr. Julia Burnier**  
McGill University

Making Progress in Cancer Control: The Number of Cancer Deaths Avoided in Canada

**Dr. Matt Warkentin**  
University of Calgary

---

## Precision Medicine and Biomarkers

Stool microbiome profiles in colorectal cancer: Establishment of lab protocols and preliminary results obtained from patients recruited to the Atlantic Cancer Consortium

**Dr. Akinola Alafiatayo**  
Memorial University of Newfoundland

Tumor copy number alterations burden as a predictor for resistance to immune checkpoint blockade across different cancer types

**Dr. Karama Asleh**  
Atlantic Cancer Research Institute

True bench-to-bedside science: An international pilot study modeling hard-to-cure pediatric cancers to prioritize therapeutic intervention

**Miss Nadine Azzam**  
Children's Hospital of Eastern Ontario Research  
Institute

Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in HPV-associated head and neck cancer

**Dr. Julia Burnier**  
McGill University

Exploring a novel triple therapy in hard-to-treat melanomas

**Mr. Feiyang Cai**  
McGill University

Nanopore sequencing of advanced cancers identifies haplotype specific promoter methylation associated with clinically relevant HRD phenotype

**Dr. Veronika Csizmok**  
Canada's Michael Smith Genome Sciences  
Centre at BC Cancer

Monitoring Epithelial Cell Subtypes in Whole Blood RNA of Prostate Cancer Patients: A Step Towards Precision Oncology

**Miss Seta Derderian**  
RI-MUHC

KEAP1/NRF2 mutations in stem cells define an aggressive subset of head and neck cancer patients who have poor prognosis, lung metastasis and therapeutic failure

**Dr. Syed Islam**  
King Faisal Specialist Hospital and Research  
Centre

Orthogonal methods independently quantify protein expression patterns associated with AKT inhibitor response in breast cancer cell lines and patient tumours

**Ms. Constance Sobsey**  
McGill University

## Health Disparities and Equity

In My Hands: Learnings from HPV-Based Self-Collection for Cervical Screening Approaches in Remote Indigenous Communities

**Mrs. Katina Pollard**  
*Métis Nation British Columbia*

Differences in the colon cancer diagnostic interval by neighbourhood income

**Ms. Laura Davis**  
*McGill University*

Patient-physician sex concordance and real-world disparities in cancer treatment practices and outcomes

**Mr. Philip Ding**  
*University of Alberta*

Through the Lens of Health Equity: Organizational Barriers to Accessing Cancer Care for People who are Highly Marginalized

**Dr. Tara Horrill**  
*University of Manitoba*

Responding to First Nations, Inuit and Métis Cancer Care Needs: Establishing & Working in Relationships to Address & Implement Culturally Safe Solutions

**Dr. Angeline Letendre**  
*Canadian Indigenous Nurses Association*

Cancer Prevention & Screening Innovation

**Dr. Angeline Letendre**  
*Canadian Indigenous Nurses Association*

**Lea Bill**  
*Alberta First Nations Information Governance Centre and First Nations Advisor to CPAC*

Identifying best practices for engaging First Nations, Inuit, and Métis stakeholders in Patient and Family Advisory Committees

**Ms. Alexandria McRorie**  
*University of Calgary*

Interventions designed to increase the uptake of lung cancer screening: an equity-oriented scoping review

**Dr. Ambreen Sayani**  
*Women's College Hospital*

Advancing health equity within the pan-Canadian Cancer Data Strategy

**Mrs. Kim Tran**  
*Canadian Partnership Against Cancer*

---

## Pediatric Cancer

Impact of Early Phase Study Enrollment for Pediatric Oncology Patients on Symptom Burden and Quality of Life: Feasibility

**Dr. Lesleigh S Abbott**  
*CHEO*

Alternative Polyadenylation in Noradrenergic to Mesenchymal Transition in Neuroblastoma

**Ms. Rhea Ahluwalia**  
*University of Toronto*

Investigating the role of active beta-catenin (ABC) in promoting metastatic disease in pediatric osteosarcoma

**Dr. Kristin Hinton**  
*University of Alberta*

Genome-wide CRISPR screening identifies the E3 ubiquitin ligase HERC1 as a driver of resistance to nucleoside analogs in acute myeloid leukemia

**Mrs. Maja Jankovic**  
*McGill University, Lady Davis Institute for Medical Research*

Defining the cellular and molecular characteristics of relapsing Wilms Tumors using single-cell genomics

**Dr. Tobias Karakach**  
*Dalhousie University*

CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to Navitoclax

**Prof. Frederick A. Mallette**  
*Université de Montréal, Maisonneuve-Rosemont Hospital Research Center*

Exploring the Possible: 3CTN-C17 Initiatives Used as Incentives to Overcome Barriers to Clinical Trial Access for Pediatric Cancer Patients

**Mr. James Schoales**  
*Canadian Cancer Clinical Trials Network (3CTN)*

**Ms. Kathy Brodeur-Robb**  
*C17 Council*

Inferring parent-of-origin of germline variants in diverse hereditary cancer syndromes without parental data

**Dr. Kasmintan Schrader**  
*BC Cancer*

Lmo2-induced T-cell acute lymphoblastic leukemia can switch addiction from initiating Lmo2/Lyl1 oncogenes to driving oncogenic Notch1

**Dr. Cedric Tremblay**  
*University of Manitoba*

**11:10 am**

**Break**

**Adolescent and Young Adult Cancer**

Chair:

**Dr. Uri Tabori**  
The Hospital for Sick Children

**Karen Haas**  
Patient Partner

CANON – The Canadian Adolescents and young adults NeuroOncology Network: From discovery to patient care

Developing a machine learning classifier for the diagnosis of Li-Fraumeni Syndrome

Investigation of RAS-dependent and -independent functions of NF1: implications for targeted and immune therapies in melanoma

Sponsored by:



**Dr. Uri Tabori**  
The Hospital for Sick Children

**Ms. Brianne Laverty**  
The Hospital for Sick Children

**Dr. Ian Watson**  
McGill University

**Tumour Microenvironment**

Chair:

**Dr. J. Patrick Murphy**  
Department of Biology, University of Prince Edward Island, Department of Pathology, University of Prince Edward Island, Beatrice Hunter Cancer Research Institute

**Megan Emily Quintal**  
Patient Partner

Prognosis and chemoresistance in ovarian cancer: the role of immune marker expression

A new patient-derived organoid culture with adipocytes allows the identification of de novo resistant ER+ breast tumors to endocrine therapies

Nuclear localization deficient IL-33 orchestrates a potent anti-tumorigenic microenvironment via the recruitment and programming of glioma inhibitory macrophage

The role of ICAM1 in glioblastoma tumorigenesis under hypoxic conditions

**Dr. Arvind Mer**  
University of Ottawa

**Dr. Afshin Raouf**  
University of Manitoba

**Mr. Shyam Menon**  
Lady Davis Institute, McGill University

**Ms. Kaviya Devaraja**  
University of Toronto

**Respecting Partnerships, Governance and Information for Change in First Nations, Inuit and Métis Cancer Care**

Chair:

**Ms. Emily Bear**  
University of Saskatchewan

**Louise Bird**  
Patient Partner

The Need For, Development, and Implementation of the Indigenous Data Governance Matters process at Ontario Health

The CINA Regional Initiatives Dashboard: Streamlining Cancer Research Collaboration

An environmental scan led by the Alberta First Nations Information Governance Centre (AFNIGC)

**Mrs. Lisa Ellison**  
Ontario Health

**Mr. Oscar Oneill**  
Canadian Indigenous Nurses Association

**Angeline Letendre**  
Canadian Indigenous Nurses Association

**Lea Bill**  
Alberta First Nations Information Governance Centre and First Nations Advisor to CPAC

## Crises Affecting Healthcare

Chair:

### **Dr. Robin Urquhart**

*Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority*

### **Jennifer Coish**

*Patient Partner*

Models of Care to Support the Cancer Workforce

Red River Métis' barriers to access and health equities throughout a cancer journey: a qualitative study

Master the HHR Crisis through Innovation and Partnerships: Highlights of the Nova Scotia Health Cancer Care Program Successes and Challenges

### **Dr. Craig Earle**

*Canadian Partnership Against Cancer*

### **Ms. Chantal Perchotte**

*Manitoba Métis Federation*

### **Dr. Helmut Hollenhorst**

*Nova Scotia Health Cancer Care Program, Dalhousie University*

---

## Canadian Partnership for Tomorrow's Health: Canada's Largest Population Laboratory for Cancer Research

Chair:

### **Dr. Philip Awadalla**

*Ontario Institute for Cancer Research, University of Toronto, Ontario Health Study, CanPath*

### **Pauline McIntyre**

*Patient Partner*

Risk factors for early-onset colorectal cancer: An analysis of Canadian prospective cohort studies

A Digital Health and Artificial Intelligence based Public Health Platform for Cancer Risk Prediction for Population-Level Cancer Prevention

Changes in breast and cervical cancer screening during the COVID-19 pandemic: findings from Alberta's Tomorrow Project

Harnessing data in the CARTaGENE Study in building prevention research program: from environmental factors to biomarkers in cancer prevention

### **Dr. Dylan O'Sullivan**

*Alberta Health Services, University of Calgary*

### **Dr. Samina Abidi**

*Dalhousie University*

### **Dr. Sara Nejatnamini**

*Alberta Health Services*

### **Dr. Vikki Ho**

*University of Montreal, University of Montreal Hospital Research Centre (CRCHUM)*

---

## Fireside Chat -From Building Health Services and Policy Research into your Career to Building a Career in Health Services and Policy Research

### **Dr. Stuart Peacock**

*Canadian Centre for Applied Research in Cancer Control (ARCC)*

### **Dr. Cynthia Kendall**

*Dalhousie University*

### **Dr. Katrin Julia Kaal**

*Nova Scotia Health*

### **Dr. Colleen Cuthbert**

*University of Calgary*

### **Dr. Theresa Tsui**

*Hospital for Sick Children and University of Toronto*

**1:10 pm**

**Lunch and Poster and Exhibit Session**

Sponsored by:



**1:30 – CCRA Open Meeting**

Chairs:

**Dr. Sachin Katyal***University of Manitoba, CancerCare Manitoba***Ms. Ruth Ackerman***Patient Partner*

Multiple myeloma: a bench-to-bedside perspective with patients as partners

**Dr. Tony Reiman***Beatrice Hunter Cancer Research Institute, Dalhousie University, University of New Brunswick*

Understanding clonal evolution in recurrent medulloblastoma: In vivo modeling and cancer-selective drug discovery and design

**Dr. Sheila Singh***Cancer Research Centre, McMaster University*

Family Ties to Cancer: Innovative primary care strategies for hereditary cancer risk

**Dr. June Carroll***Faculty of Medicine, University of Toronto, Granovsky Gluskin Family Medicine Centre, Sinai Health*

Break

## CONCURRENT SESSIONS

**The Gut Microbiome for Precision Oncology**

Chair:

**Dr. Bertrand Routy***CHUM / CRCHUM***Darren Frew***Patient Partner*

The rapid development of the gut microbiome as one of the hallmarks of cancer

**Dr. Bertrand Routy***CHUM / CRCHUM*

Distinct gut microbiome clusters in high-grade prostate cancer patients influence the antitumor efficacy of anti-PD-1 immunotherapy in mice

**Mr. Jalal Laaraj***Centre de Recherche du CHU de Québec-Université Laval*

The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids

**Mr. Jalal Laaraj***Centre de Recherche du CHU de Québec-Université Laval*

Linking tumour, blood and oral microbiomes with cancer outcomes

**Dr. Robyn Wright***Dalhousie University***Advances in Cancer Biology**

Chair:

**Dr. Paola Marcato***Department of Pathology, Dalhousie University***Dr. John K Mark***Patient Partner*

Genome-Wide CRISPR Cas9 Screen Reveals a PARG - PTEN - Dependent Vulnerability in Melanoma

**Mr. Emmanuel Asante***McGill University*

Cataloguing and characterizing the chromosomes affected by genomic cataclysms in mantle cell lymphoma

**Dr. Krysta Coyle***Simon Fraser University*

Improving the cancer survivorship narrative by implanting artificial Intelligence along the health care continuum

**Dr. Paola Marignani***Dalhousie University*

Chair:

**Talia Pfefferle**

*Canadian Partnership Against Cancer*

National Indigenous Healthcare Provider Organization Response to First Nations, Inuit and Metis Cancer and Cancer Care Needs: Outcomes from a Cultural Safety Readiness Survey

**Dr. Angeline Letendre**

*Canadian Indigenous Nurses Association*

**Marilee Nowgesic**

*Canadian Indigenous Nurses Association*

Mi'kmaq Birch Bark extract: a new potential treatment for cancer

**Dr. Stacey Ann Dmello Peters**

*Cape Breton University*

The Linguistic Indicators of Framing Tool: LIFTing harmful and deficit-based language out of cancer care and academic settings that involve Indigenous peoples

**Dr. Jessica Chan**

*University of British Columbia*

**Dr. Amy Shawanda**

*McGill University*

---

**Overcoming Treatment Resistance in Cancers**

Chair:

**Isabelle Allain**

*Patient Partner*

**Dr. Franco Vizeacoumar**

*Saskatchewan Cancer Agency, University of Saskatchewan*

Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells

**Dr. Grant Brown**

*University of Toronto*

Targeting telomerase by synthetic dosage lethality

**Mr. Vincent Maranda**

*University of Saskatchewan*

Identifying cell cycle mediators as essential therapeutic vulnerabilities in cancers with non-V600 BRAF mutations

**Dr. Melody Riaud**

*Lady Davis Institute*

Bintrafusp alfa improves survival in ovarian cancer models by promoting T effector memory responses

**Dr. Andrew Craig**

*Queen's University*

---

**WORKSHOP – Patient Engagement****Dr. Caroline Jose**

*Vitalité Health Network*

**Ms. Kimberly Badovinac**

*Canadian Cancer Research Alliance, Canadian Partnership Against Cancer*

**Dr. Robin Urquhart**

*Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority*

**Dr. Ambreen Sayani**

*Women's College Hospital*

**Ms. Adrienne Co-Dyre**

*Patient Partner*

6:15 am

Terry Fox Run

8:00 am

Breakfast

9:00 am

CONCURRENT SESSIONS

---

## Reducing Your Risk of Cancer

Chair:

**Shantelle Gould**

*Patient Partner*

**Dr. Rachel Murphy**

*BC Cancer Research Centre, University of British Columbia*

You are what you eat but what if you are where you live?

There is kind of this awkward pressure that I should be doing it: Factors influencing youth vaping uptake

Exploring the Etiology of Rare Cancers Using a Large Occupational Cohort

The effectiveness and cost-effectiveness of population-level policies to reduce alcohol use: a systematic umbrella review

**Dr. Rachel Murphy**

*BC Cancer Research Centre, University of British Columbia*

**Dr. Laura Struik**

*University of British Columbia*

**Dr. Paul Demers**

*Occupational Cancer Research Centre, Ontario Health*

**Ms. Umaima Abbas**

*University of Western Ontario*

---

## Recent Advances in Cancer Treatments

Chair:

**Dr. Franco Vizeacoumar**

*Saskatchewan Cancer Agency, University of Saskatchewan*

**John Corriveau**

*Patient Partner*

Unique transcriptome profile at the leading edge of tumours point to the therapeutic vulnerabilities

Investigation of novel anti-leukemic compounds uncovered through high-throughput screening of human model leukemias

EZH2 inhibition circumvents PRAME-mediated retinoid resistance in keratinocyte carcinomas

Targeting colorectal liver metastases with Alpha radiation emitting device - A pre-clinical study

**Dr. Pinaki Bose**

*University of Calgary*

**Mrs. Karla Lucia Paez Martinez**

*Université de Montréal*

**Mr. Brandon Ramchatesingh**

*McGill University*

**Dr. Oran Zlotnik**

*McGill University Health Center Research Institute*

---

## Supporting First Nations, Inuit and Métis Cancer Strategies through Research

Chair:

**Dr. Brenda Elias**

*University of Manitoba*

Alberta Métis Cancer Strategy

Walking Together to Strengthen Indigenous Cancer Care in Alberta: Our North Star to Action

**Miss Amanda Andrew**

*Métis Nation of Alberta*

**Mr. Chris Carriere**

*CancerCare Alberta*

**Ms. Catherine Dixon**

*Northwest Territories Health and Social Services Authority*

## Networked Cancer Research in Canada

Chair:

### Dr. Sherri Christian

Memorial University of Newfoundland, Beatrice Hunter Cancer Research Institute, Marathon of Hope Cancer Centres, Terry Fox Research Institute

### Wayne Olford

Patient Partner

Canadian Pediatric Cancer Consortium: Advancing Childhood Cancer Experience, Science and Survivorship

### Dr. Christine Williams

Ontario Institute for Cancer Research, Canadian Pediatric Cancer Consortium

PRrecision Oncology For Young peopLE (PROFYLE): The pan-Canadian precision oncology program for children, adolescents and young adults with cancer

### Ms. Stephanie Grover

The Hospital for Sick Children, PRrecision Oncology For Young peopLE (PROFYLE)

Terry Fox Research Institute, Marathon of Hope Cancer Centres Network

### Dr. Isabel Serrano

Terry Fox Research Institute, Marathon of Hope Cancer Centres Network

Using CanPath to study the earliest signatures of cancer development

### Dr. Philip Awadalla

Ontario Institute for Cancer Research, University of Toronto, Ontario Health Study, CanPath

---

## Multi-omics and Epigenetics

Chair:

### Dr. Touati Benoukraf

Memorial University of Newfoundland

### Anita Hamilton

Patient Partner

Characterizing the Interplay of Multi-Omics Mechanisms in Cancers

### Dr. Touati Benoukraf

Memorial University of Newfoundland

Developmental epigenomic origins of Group 3 and 4 medulloblastoma

### Dr. Shraddha Pai

Ontario Institute for Cancer Research

Defining functional metabolites in cancer by combining metabolomics and target engagement proteomics

### Dr. J. Patrick Murphy

University of Prince Edward Island

Embracing complexity to achieve precision: multilayer cell fate control in cancer

### Dr. Hong Han

McMaster University

**10:30 am**

**Transition**

**10:40 am**

**LIGHTNING SESSIONS**

---

## Metabolism

XPO1/CRM1 inhibition modulates autophagy and protein metabolism in cancer cells

### Mrs. Sophie Landry

Université de Moncton

ALDH1A3 regulates key processes that required for breast cancer cell plasticity and progression

### Dr. Wasundara Fernando

Dalhousie University

Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations

### Ms. Helgi Kuzmychova

University of Manitoba

Fatty acid  $\beta$ -oxidation enzyme EC11 drives aggressive prostate cancer phenotype and predicts poor clinical outcome

### Dr. Jacques Lapointe

McGill University

Delineating and targeting a novel metabolism-based post-translational mechanism regulating the abundance of the 'undruggable' oncoprotein c-MYC in medulloblastoma

### Emma Martell

University of Manitoba

The secret life of a Krebs Cycle enzyme in aggressive cancers and optic neuropathies

### Dr. Michael Moran

Hospital for Sick Children, University of Toronto

---

## Patient Experience and Advocacy

Co-creation of a patient engagement strategy in cancer research funding

**Ms. Suzanne Bays**  
*Canadian Cancer Society*

Prostatic Specific Antigen Screening and Prostate Biopsy Procedure Experiences for Men at Risk of Prostate Cancer: Preliminary Results of the Biomarkers and Prostate Cancer Prevention and Environment (BIOCaPPE) Study

**Mr. Donald Wood**  
*Canadian Cancer Society*

**Mrs. Farah Ben Souilah**  
*CHU de Québec, Université Laval*

Mental Health Among People Living With and Beyond Colorectal Cancer: A Patient-Oriented Constructivist Grounded Theory

**Dr. Vicki Cheng**  
*University of British Columbia*

The Rethinking Clinical Trials (REaCT) program: transforming pragmatic, practice-changing, patient-centred research across Canada

**Dr. Marie-France Savard**  
*The Ottawa Hospital Research Institute*

Ethical issues experienced in relationships between patients and other team members developing a strategy for meaningful patient engagement in cancer research funding

**Dr. Jenny Leese**  
*University of Ottawa*

How do patients with hereditary cancer syndromes navigate the healthcare system? A qualitative comparative study across Canada

**Ms. Brooklyn Sparkes**  
*Memorial University of Newfoundland*

Ethics as an enabler in co-design: Example of the Alberta Cancer Diagnosis Initiative

**Dr. Fay Strohschein**  
*University of Calgary, Alberta Health Services*

Mise à l'échelle du programme PAROLE-Onco: Le partenariat de soins et de services au bénéfice des patients et de leurs proches touchés par le cancer pour améliorer leur expérience tout au long de la trajectoire de soins

**Mrs. Cécile Vialaron**  
*Centre de recherche du CHUM*

---

## Drug Discovery, Design, Delivery and Resistance

Spatiotemporal modelling of chemoresistance evolution in breast tumors uncovers key dependencies on SLC38A7 and SLC46A1

**Dr. Yannick Audet-Delage**  
*University of Ottawa*

Best evidences for the existence of anti-cancer fibroblasts

**Prof. Jean-Philippe Brosseau**  
*Université de Sherbrooke*

The Role of Ceramide Metabolism in Temozolomide Chemoresistance in Glioblastoma

**Dr. Simone C. da Silva Rosa**  
*University of Manitoba*

Synergistic co-targeting of the thioredoxin and glutathione antioxidant systems in glioblastoma cells with aberrant EGFR expression

**Dr. Elvis Martinez-Jaramillo**  
*McGill University*

Utilization of high-content imaging and bioactivity assays for drug screening of metallotherapeutic anticancer agents

**Mr. Brian Park**  
*Bold Therapeutics*

Ex vivo testing of Ran GTPase inhibitors in human ovarian cancer samples via microfluidics models

**Sabrina Ritch**  
*CRCHUM*

## Genetics and Epigenetics

A systematic approach to studying the effect of cancer histone mutations

**Dr. Maria Aristizabal**  
*Queen's University*

Targeting the histone methylation in cancer: the balance of H3K27 and H3K36 methylation

**Dr. Dalia Barsyte-Lovejoy**  
*University of Toronto*

EZHIP, a new oncogene in osteosarcoma

**Dr. Geoffroy Danieau**  
*Research Institute of the McGill University Health Centre*

Hypermethylation and Silencing Associated With Poor Prognosis In HPV Positive Head and Neck Cancer

**Ms. Fatemeh Farshadi**  
*McGill University, Lady Davis institute*

Understanding the Translational Landscape of High-Risk Basal Cell Carcinoma

**Miss Sarah Ghezelbash**  
*Lady Davis Institute, McGill University*

The Functional Role of Chromosome 4p Loss in Triple Negative Breast Cancer

**Miss Lynn Karam**  
*Concordia University*

Deciphering the role of epigenetic combination therapies in ovarian cancer

**Mr. Marios Langke**  
*McGill University*

Regulation of TAZ expression by epigenetic modulators for the treatment of multiple myeloma

**Dr. Aimee Wong**  
*University of New Brunswick*

Association between sleep characteristics and cancer survival: a Mendelian randomization study

**Dr. Lin Yang**  
*Alberta Health Services*

---

## Cancer Risk and Primary Prevention

Association between traffic-related air pollution and breast cancer risk in post-menopausal women in Alberta's Tomorrow Project

**Ms. Mohadeseh Ahmadi**  
*University of British Columbia*

Oral co-infection with multiple alpha-human papillomavirus and head and neck cancer risk

**Mary Amure**  
*McGill University*

Depression, Anxiety and the Risk of Cancer: An Individual-Participant Data Meta-Analysis

**Mr. Yunsong Cui**  
*Atlantic PATH, Dalhousie University*

Examining the association between ambient exposure to nitrogen dioxide and breast cancer risk among high-risk Canadian women

**Ms. Katherine Pulella**  
*University of Toronto*

The Nova Scotia Community Cancer Matrix (NS-Matrix): using small-area mapping of preventable cancers to inform and strengthen cancer prevention interventions

**Dr. Nathalie Saint-Jacques**  
*Nova Scotia Health*

A "Sex Gap" in occupational lung cancer? Exploring sex-differences in lung cancer risk among Ontario workers

**Dr. Jevana Sritharan**  
*Ontario Health*

Predicting the risk of high-risk colorectal adenomas with markers of glucose metabolism and liver function at the time of screening colonoscopy

**Mr. R. Liam Sutherland**  
*University of Sutherland*

**11:10 am**

**Break**

**11:40 am**

## Plenary Session – Environment and Cancer

Chairs:

### Dr. Robin Urquhart

*Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority*

### Dr. Don Desserud

*Patient Partner*

Indigenous-led Conversation and Environmental Wellness

**Ms. Carol Crowe**  
*Indigenous Visions Inc.*

Lifetime radon exposure as a future lung cancer screening eligibility criterion in Canada: pilot study outcomes and upcoming clinical trial details

**Dr. Aaron Goodarzi**  
*Cumming School of Medicine, University of Calgary*

Climate, Health & Sustainable Care

**Dr. Fiona Miller**  
*Centre for Sustainable Health Systems, Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto*

**Closing Remarks**

**Dr. Sara Urowitz**

*Canadian Cancer Research Alliance, Canadian Partnership Against Cancer*

**Dr. Louisa Salemi**

*Canadian Cancer Research Alliance, Canadian Partnership Against Cancer*

**Catherine Martin**

*Director Indigenous Engagement, Member of Millbrook Mi'kmaw community*

---

November 2023